New Statistical Method Provides Timely Comparative Effectiveness Research

Published Sep 17, 2012
Boston, MA, USA - Health care companies face increased pressure to compare the effectiveness of new treatments as early as possible. A study published in Value in Health reports on a novel statistical method that can be used to compare approved treatments even early in the product’s life cycle. Researchers at Analysis Group Inc., a health economic consultancy in Boston, MA, and at Shire Development LLC, in Wayne, PA, illustrate in their report how the method works. In their article, “Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research,” the authors discuss the application of this method in the areas of oncology, dermatology, diabetes, and attention-deficit hyperactivity disorder. While randomized head-to-head trials are the gold standard for comparing treatments, the new approach can provide indirect comparative evidence when such trials are not available. “The key is to fully leverage clinical trial data from pharmaceutical or device manufacturers,” says James Signorovitch, PhD, of Analysis Group, lead author of the article. Generally, clinical trials used to gain regulatory approval for new drugs or devices do not include comparisons of competing products. The study’s authors address this by using detailed patient data from the new product’s trials to match populations studied in published trials of competing products. Treatment outcomes are then evaluated between comparable populations. The article was sponsored by Shire Development LLC. Assistance with the writing of this press release was provided by Shire Development LLC.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.

Advancing the Economics of Mental Health: A Global Perspective

Mar 12, 2025

Value in Health, the official journal of ISPOR announced the publication of a special themed section of research papers exploring mental health economics, highlighting impacts on caregivers, productivity, and interventions’ cost-effectiveness.

Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds

Feb 11, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of an ISPOR Working Group Report that provides an introduction to the uses of generative artificial intelligence (AI) in health technology assessment (HTA).
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×